COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

被引：0
|
作者：
Nguyen, T. T. T. [1 ]
Yagudina, R. [2 ]
Kulikov, A. U. [3 ]
机构：
[1] First Moscow State Med Univ Named Sechenov, Moscow, Russia
[2] Moscow Med Acad, Lab Pharmacoecon, Moscow, Russia
[3] Moscow Med Acad, Moscow, Russia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.916
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANA LYSIS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. C.
    Nguyen, T. T. T.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A735 - A735
  • [2] Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
    Lidgren, M.
    Joensson, B.
    Rehnberg, C.
    Willking, N.
    Bergh, J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (03) : 487 - 495
  • [3] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in polish setting
    Orlewska, E.
    Pienkowski, T.
    Drosik, K.
    Gyldmark, M.
    Aultman, R.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A125 - A125
  • [4] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [5] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [6] Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)
    Quintyne, K. I.
    Woulfe, B.
    Dee, A.
    Gupta, R.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt
    Elsisi, Gihan Hamdy
    Nada, Yousery
    Rashad, Noha
    Carapinha, Joao
    Noor, Ahmad O.
    Almasri, Diena M.
    Al Zaidy, Mostafa
    Foad, Ahmed
    Khaled, Hussien
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (06) : 575 - 580
  • [8] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    [J]. PLOS ONE, 2019, 14 (06):
  • [9] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    [J]. CANCER, 2007, 110 (03) : 489 - 498
  • [10] Cost-effectiveness of adjuvant chemotherapy plus trastuzumab (T) in HER2-positive breast cancer
    Liberato, N. L.
    Marchetti, M.
    Barosi, G.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI6 - XI6
12345